vs
Side-by-side financial comparison of MEDIFAST INC (MED) and NATURES SUNSHINE PRODUCTS INC (NATR). Click either name above to swap in a different company.
NATURES SUNSHINE PRODUCTS INC is the larger business by last-quarter revenue ($123.8M vs $75.1M, roughly 1.6× MEDIFAST INC). On growth, NATURES SUNSHINE PRODUCTS INC posted the faster year-over-year revenue change (4.7% vs -36.9%). NATURES SUNSHINE PRODUCTS INC produced more free cash flow last quarter ($7.6M vs $-6.6M). Over the past eight quarters, NATURES SUNSHINE PRODUCTS INC's revenue compounded faster (5.6% CAGR vs -34.4%).
Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.
Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.
MED vs NATR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $75.1M | $123.8M |
| Net Profit | — | $4.1M |
| Gross Margin | 69.4% | 72.5% |
| Operating Margin | -10.4% | 4.3% |
| Net Margin | — | 3.3% |
| Revenue YoY | -36.9% | 4.7% |
| Net Profit YoY | — | 1379.4% |
| EPS (diluted) | $-1.64 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $75.1M | $123.8M | ||
| Q3 25 | $89.4M | $128.3M | ||
| Q2 25 | $105.6M | $114.8M | ||
| Q1 25 | $115.7M | $113.2M | ||
| Q4 24 | $119.0M | $118.2M | ||
| Q3 24 | $140.2M | $114.6M | ||
| Q2 24 | $168.6M | $110.6M | ||
| Q1 24 | $174.7M | $111.0M |
| Q4 25 | — | $4.1M | ||
| Q3 25 | $-2.3M | $5.3M | ||
| Q2 25 | $2.5M | $5.3M | ||
| Q1 25 | $-772.0K | $4.7M | ||
| Q4 24 | — | $-321.0K | ||
| Q3 24 | $1.1M | $4.3M | ||
| Q2 24 | $-8.2M | $1.3M | ||
| Q1 24 | $8.3M | $2.3M |
| Q4 25 | 69.4% | 72.5% | ||
| Q3 25 | 69.5% | 73.3% | ||
| Q2 25 | 72.6% | 71.7% | ||
| Q1 25 | 72.8% | 72.1% | ||
| Q4 24 | 74.1% | 72.0% | ||
| Q3 24 | 75.4% | 71.3% | ||
| Q2 24 | 73.2% | 71.4% | ||
| Q1 24 | 72.8% | 71.2% |
| Q4 25 | -10.4% | 4.3% | ||
| Q3 25 | -4.6% | 7.0% | ||
| Q2 25 | -1.0% | 3.7% | ||
| Q1 25 | -1.1% | 5.4% | ||
| Q4 24 | 0.6% | 3.8% | ||
| Q3 24 | 1.5% | 4.6% | ||
| Q2 24 | -4.7% | 5.1% | ||
| Q1 24 | 4.5% | 4.2% |
| Q4 25 | — | 3.3% | ||
| Q3 25 | -2.5% | 4.2% | ||
| Q2 25 | 2.3% | 4.6% | ||
| Q1 25 | -0.7% | 4.2% | ||
| Q4 24 | — | -0.3% | ||
| Q3 24 | 0.8% | 3.8% | ||
| Q2 24 | -4.8% | 1.2% | ||
| Q1 24 | 4.8% | 2.1% |
| Q4 25 | $-1.64 | $0.23 | ||
| Q3 25 | $-0.21 | $0.30 | ||
| Q2 25 | $0.22 | $0.28 | ||
| Q1 25 | $-0.07 | $0.25 | ||
| Q4 24 | $0.08 | $-0.02 | ||
| Q3 24 | $0.10 | $0.23 | ||
| Q2 24 | $-0.75 | $0.07 | ||
| Q1 24 | $0.76 | $0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.3M | $93.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $198.9M | $161.6M |
| Total Assets | $248.0M | $261.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.3M | $93.9M | ||
| Q3 25 | $173.5M | $95.6M | ||
| Q2 25 | $162.7M | $81.3M | ||
| Q1 25 | $164.6M | $86.5M | ||
| Q4 24 | $162.3M | $84.7M | ||
| Q3 24 | $170.0M | $78.7M | ||
| Q2 24 | $163.5M | $68.7M | ||
| Q1 24 | $156.4M | $77.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $2.1M |
| Q4 25 | $198.9M | $161.6M | ||
| Q3 25 | $214.7M | $166.7M | ||
| Q2 25 | $216.0M | $163.7M | ||
| Q1 25 | $211.0M | $167.1M | ||
| Q4 24 | $210.1M | $161.0M | ||
| Q3 24 | $207.3M | $162.6M | ||
| Q2 24 | $205.3M | $156.4M | ||
| Q1 24 | $211.0M | $159.7M |
| Q4 25 | $248.0M | $261.1M | ||
| Q3 25 | $268.2M | $264.8M | ||
| Q2 25 | $269.3M | $254.9M | ||
| Q1 25 | $280.0M | $252.7M | ||
| Q4 24 | $284.2M | $240.9M | ||
| Q3 24 | $291.2M | $245.3M | ||
| Q2 24 | $293.5M | $235.8M | ||
| Q1 24 | $302.8M | $247.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.01× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.3M | $9.9M |
| Free Cash FlowOCF − Capex | $-6.6M | $7.6M |
| FCF MarginFCF / Revenue | -8.8% | 6.1% |
| Capex IntensityCapex / Revenue | 1.8% | 1.9% |
| Cash ConversionOCF / Net Profit | — | 2.41× |
| TTM Free Cash FlowTrailing 4 quarters | $1.2M | $28.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.3M | $9.9M | ||
| Q3 25 | $12.1M | $18.5M | ||
| Q2 25 | $-3.4M | $4.3M | ||
| Q1 25 | $3.4M | $2.6M | ||
| Q4 24 | $-4.9M | $12.2M | ||
| Q3 24 | $9.1M | $9.6M | ||
| Q2 24 | $13.1M | $1.3M | ||
| Q1 24 | $7.3M | $2.2M |
| Q4 25 | $-6.6M | $7.6M | ||
| Q3 25 | $10.8M | $16.8M | ||
| Q2 25 | $-4.8M | $3.0M | ||
| Q1 25 | $1.9M | $1.5M | ||
| Q4 24 | $-7.2M | $10.0M | ||
| Q3 24 | $7.7M | $7.9M | ||
| Q2 24 | $11.1M | $-2.0M | ||
| Q1 24 | $5.4M | $-1.5M |
| Q4 25 | -8.8% | 6.1% | ||
| Q3 25 | 12.0% | 13.1% | ||
| Q2 25 | -4.5% | 2.6% | ||
| Q1 25 | 1.6% | 1.3% | ||
| Q4 24 | -6.1% | 8.5% | ||
| Q3 24 | 5.5% | 6.9% | ||
| Q2 24 | 6.6% | -1.9% | ||
| Q1 24 | 3.1% | -1.4% |
| Q4 25 | 1.8% | 1.9% | ||
| Q3 25 | 1.5% | 1.3% | ||
| Q2 25 | 1.3% | 1.2% | ||
| Q1 25 | 1.3% | 1.0% | ||
| Q4 24 | 1.9% | 1.9% | ||
| Q3 24 | 1.0% | 1.5% | ||
| Q2 24 | 1.1% | 3.0% | ||
| Q1 24 | 1.1% | 3.3% |
| Q4 25 | — | 2.41× | ||
| Q3 25 | — | 3.46× | ||
| Q2 25 | -1.36× | 0.81× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | — | ||
| Q3 24 | 8.04× | 2.21× | ||
| Q2 24 | — | 0.97× | ||
| Q1 24 | 0.88× | 0.94× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MED
Segment breakdown not available.
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
